Why the study?
Does a 96-hour continuous infusion of Adriamycin achieve comparable cellular concentrations to bolus injection in patients with advanced multiple myeloma?
Population
7 patients with advanced multiple myeloma
Comparison
Adriamycin administered as a 96-hour continuous… vs Bolus injection (rapid injection of total dose)
Design
Case_series
Follow-up
96 hours
Authors
Loading...
Hypothesis-generating for less toxic continuous Adriamycin infusion; leaves open clinical benefit in advanced multiple myeloma.
Does a 96-hour continuous infusion of Adriamycin achieve comparable cellular concentrations to bolus injection in patients with advanced multiple myeloma?
A 96-hour continuous infusion of Adriamycin achieves comparable cellular drug exposure to bolus injection despite lower plasma concentrations, potentially offering a less toxic administration method.
Speth et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: